Introduction
============

Chronic obstructive lung disease is characterized by airflow limitation and chronic airway inflammation and it is expected to be the third leading cause of death in 2030[@B1]. In the natural course of chronic obstructive pulmonary disease (COPD), acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a critical event leading to poorer outcomes of COPD. AECOPD is clinically defined as the events of increasing respiratory symptoms including dyspnea, cough, and sputum production, and increased sputum purulence[@B2][@B3]. It is manifested with the exaggerated airway inflammation and bronchial obstruction.

AECOPD is a trigger for catastrophic cascades in COPD and it is one of the most important risk predictor for subsequent exacerbation, lung function decline, and mortality [@B4][@B5]. Severe AECOPD requires hospitalization or visiting the emergency room and it may be associated with acute respiratory failure. One-year mortality of patients with AECOPD requiring noninvasive ventilation (NIV) and intensive care unit (ICU) care is reported to be as high as 28% and 43%, respectively[@B6]. Therefore, prevention of AECOPD is one of the most important goal in manging COPD. Once AECOPD develops, early recovery is crucial in determining prognosis of patients with COPD and delayed recovery from exacerbation accelerates decline in forced expiratory volume in 1 second (FEV~1~)[@B7]. Therefore, as well as prevention of AECOPD, efforts to recover from the disaster as soon as possible is required.

In this review, recent updates for management of AECOPD will be discussed with special focus on the patients with acute respiratory failure and life-threatening exacerbation.

Updated Management of AECOPD with Acute Respiratory Failure
===========================================================

1. Pharmacological treatment
----------------------------

Short acting bronchodilators (short-acting inhaled β2-agnosits, with or without short-acting anticholinergics) are recommended as an initial choice to treat an AECOPD[@B8]. The short acting bronchodilators can be administered using nebulizer or metered dose inhaler (MDI) with spacer. Even though the emitted dose of drug is larger in nebulizer than MDI plus spacer, relative lung deposition of short acting bronchodilator following inhalation in AECOPD is similar in both delivery systems[@B9]. Long-acting bronchodilators also should be applied as soon as possible in AECOPD.

Systemic steroids is a cornerstone of treating AECOPD and it can improve FEV~1~, oxygenation, shorten recovery time, and hospital stay. Some data suggested the association between response to corticosteroids and blood eosinophil count[@B10]. Recently, American Thoracic Society/European Respiratory Society reported updated clinical recommendation for treating AECOPD in terms of six key questions including "Should oral corticosteroids be used to treat ambulatory patients who are having a COPD exacerbation?"[@B8]. It recommended a short course of oral corticosteroids even for ambulatory patients with AECOPD.

Although the roles of antibiotics in AECOPD have been debated, antibiotics can be used when patients have clinical sings of bacterial infection such as increased sputum and purulence. In a systemic review of placebo-controlled studies, antibiotics reduced short-term mortality, treatment failure, and sputum purulence[@B10].

2. Non-pharmacological ventilatory support
------------------------------------------

AECOPD with respiratory failure can be manifested with hypoxemic respiratory failure and/or ventilatory failure. Supplementary oxygen is essential to improve patient\'s hypoxemia and it should be titrated as treatment goes on with target saturation of 88%--92% and assessing CO~2~ retention[@B11][@B12].

If respiratory acidosis progresses despite proper pharmacological and oxygen therapy, ventilatory support should be considered and applied to treat acute respiratory failure. Until now, whereas NIV is regarded as the first choice for ventilatory support in AECOPD, the following some adjunctive strategies with NIV and high-flow nasal cannula (HFNC) oxygen therapy may have limited controlled trials and evidence for in AECOPD. However, recent updated reports may be helpful in managing AECOPD with respiratory failure and show a breakthrough point in current practice.

### 1) Non-invasive ventilation

NIV is preferentially recommended in AECOPD over invasive mechanical ventilation with intubation[@B12][@B13]. Trends in mechanical ventilation among patients with AECOPD have been changed. For an example in U.K., all mechanical ventilatory support has been increased[@B14]. Initial NIV increased by 15.1% yearly while invasive mechanical ventilation declined by 3.2% as shown in [Figure 1](#F1){ref-type="fig"} and the trends is predominant as the frequency of administration was increased and in patients without pneumonia[@B14]. NIV can reduce intubation risk and complication including ventilatory associated pneumonia. It is also favored in reducing mortality[@B15]. The benefits of NIV is achieved by recruitment of collapsed alveoli and improving ventilation-perfusion imbalance resulting in improving oxygenation and respiratory acidosis. Positive ventilation will decrease work of breathing by increasing mean airway pressure and decreasing air trapping. The efficacy of NIV in acute respiratory failure due to AECOPD in terms of improving treatment failure, mortality, and intubation risk is well reviewed in remote and recent meta-analyses. Therefore, for hospitalized patients with acute or acute-on-chronic hypercapnic respiratory failure due to AECOPD, the use of NIV is strongly recommended. General indications for NIV include (1) respiratory acidosis (partial pressure of carbon dioxide \[PaCO~2~\] ≥45 mm Hg and pH ≤7.35); (2) severe dyspnea with clinical signs in use of respiratory accessary muscles, paradoxical movement, and retraction of intercostal muscles; and (3) persistent hypoxemia despite oxygen therapy.

#### (1) NIV with a helmet

When NIV is applied with a face mask, patients frequently suffer from many complications including pressure intolerance, air leak related adverse effects (sleep disruption, reduced ventilation, and eye irritation), skin erosion on nasal bridge, naso-oral airway complications (dryness, nasal congestion, rhinitis, and bleeding), and aerophagia (eructation, flatulence, and abdominal disturbance)[@B16]. Because of high complication rate, overall failure of NIV occurs in 16%--30% of patients[@B17]. NIV with a helmet was developed to improve performance and reduce complication of NIV with mask. It has advantages in terms of nutrition and hydration through patient access port, lower air leaks, no facial skin lesions, no eye irritation, and independence of the patient\'s anatomy as shown in [Figure 2](#F2){ref-type="fig"}. However, it has disadvantages for noise, larger dead space, and the risk of claustrophobia[@B17].

Despite the previous controversy on effects of oxygenation and CO~2~ retention, reduction on intubation rate and mortality, recent studies reported favorable results. For example, in a randomized controlled study in patients with adult respiratory distress syndrome (ARDS), NIV delivered by helmet showed lower mortality and decreased endotracheal intubation (absolute difference --21.4% for mortality and --43.3% for endotracheal intubation)[@B18]. Also, a recent meta-analysis of controlled studies for NIV with helmet in patients with acute respiratory failure showed that NIV with a helmet was associated with lower hospital mortality (odds ratio \[OR\], 0.43; 95% confidence interval \[CI\], 0.26--0.69; p=0.0005), intubation rate (OR, 0.32; 95% CI, 0.21--0.47; p\<0.00001), and complications (OR, 0.6; 95% CI, 0.4--0.92; p=0.02)[@B17]. However, until now, trials of NIV with helmet in patients with AECOPD have been rarely performed or tested in small population. In a small randomized controlled study recruited patients with AECOPD, there is no statistical difference in length of ICU stay, ICU mortality, NIV failure, and complications in helmet group and facial mask group[@B19]. In a multi-center short-term randomized controlled study for patients with acute hypercapnic respiratory failure, NIV with hemet significantly improved ventilation parameters (pH, PaCO~2~, partial pressure of oxygen \[PaO~2~\]/fraction of inspired oxygen \[FiO~2~\], respiration rate), heart rate, and dyspnea score than baseline level and the improved results were similar to those of oronasal mask[@B20]. Therefore, helmet may be a valid alternative option to a mask in improving gas exchange and achieving a good tolerance to NIV. However, higher level of positive end-expiratory pressure or pressure support may be required to compendate the larger dead space[@B18].

#### (2) NIV with helium-oxygen mixture

Another adjunctive treatment for NIV ever tried is the use of helium-oxygen mixture (He/O~2~). He/O~2~ has lower density than air/oxygen and it enhances transition to laminar flow and reduce density dependent components of airway resistance. Therefore, hypothetically, it is expected to reduce NIV failure rate when using He/O~2~ instead of air/oxygen in AECOPD. However, in recent meta-analysis including relevant three randomized controlled trials enrolled a total of 772 patients, He/O~2~ didn\'t reduce NIV failure rate and ICU mortality rate compared with air/oxygen[@B21]. Nevertheless, NIV with He/O~2~ was associated with less NIV-related adverse events (OR, 0.56; 95% CI, 0.4--0.8; p=0.001) and a shorter length of ICU stay (difference in means, --1.07 day; 95% CI, --2.14 to --0.004; p=0.049) in hypercapnic COPD exacerbation[@B21].

An extended prospective, randomized, open-label trial in 16 ICUs and six countries was performed to elucidate the efficacy of He/O~2~ with continuous administration for 72 hours in severe exacerbation of COPD. This trial was closed early due to low global NIV failure rate and the primary outcomes, NIV failure rate and intubation rate, were not different in He/O~2~ and air/oxygen group. In subgroup analysis for patients failed with NIV, the ventilation duration and length of ICU stay was significantly shorter in He/O~2~ [@B22]. Additionally, primary outcomes seemed to be better in trends and showed better ventilation outcomes for initial three days of treatment without final statistical significance[@B22].

#### (3) NIV with extracorporeal CO~2~ removal

Extracorporeal life support (ECLS) has been rapidly progressed for treating ARDS and expanding its indications including hypercapnic respiratory failure, bride to lung transplantation, earlier use in less severe hypoxemic respiratory failure, resuscitation of donor lungs before transplantation, and bridge to early mobility [@B23]. Extracorporeal CO~2~ removal (ECCO~2~R) as a kind of ECLS has been focused on improving hypercapnia during protective ventilation strategy in ARDS. Comparing with conventional extracorporeal membrane oxygenation, ECCO~2~R presents many advantages including a lower blood flow rate and consequently smaller veno-venous catheters ([Table 1](#T1){ref-type="table"}). Therefore, ECCO~2~R has been applied for non-ARDS hypercapnic respiratory failure as case studies or single centered prospective pilot studies[@B23]. In a multicenter retrospective randomized controlled study in patients with hypercapnic respiratory failure failing NIV, arterio-venous ECCO~2~R group avoided intubation risk (10% for intervention group vs. 100% for controlled group) and showed short term and long-term survival[@B24]. Another multicenter matched cohort study with historical control in patients with hypercapnic respiratory failure also decreased the risk of intubation to a third[@B25]. In the matched cohort study with historical control, when ECCO~2~R with NIV was applied for hypercapnic patients at risk of NIV failure, respiratory variables such as PaCO~2~, arterial pH, respiratory rate, and PaO~2~/FiO~2~ were significantly improved and cumulative incidence of endotracheal intubation (hazard ratio, 0.27; 95% CI, 0.07--0.98; p=0.047) and hospital mortality (8% vs. 35%, p=0.0347) were significantly lowered in patients applied with NIV and ECCO~2~R[@B25]. Recently, a multicenter case-control study was performed in five European ICUs to evaluate the feasibility and safety of avoiding invasive mechanical ventilation by using ECCO~2~R in patients with AECOPD and acute hypercapnic respiratory failure refractory to NIV[@B26]. Although it was a small study, the primary outcome, intubation risk was avoided in 56% of patients in the ECCO~2~R group with extracorporeal blood flow of 1.3 L/min. In this trial, major bleeding was developed in 36% of patients which was significantly higher than compared with control (8%)[@B26]. Further studies with ECCO~2~R for prevention of intubation in AECOPD, facilitating extubation, and benefits in stable COPD with chronic hypercapnic failure are ongoing.

Modern ECLS including ECCO~2~R offers new and promising therapeutic options in patients with COPD in acute on chronic respiratory failure. However, severe complications including hemorrhage and needs for further evidence on the overall efficacy in AECOPD may be obstacles to expanding clinical application of NIV with ECCO~2~R[@B23]. Also, the right indication, timing, and strategy for applying ECCO~2~R in patients with AECOPD should be further explored[@B27].

### 2) HFNC oxygen therapy

HFNC oxygen therapy can deliver a heated and humidified air flow of 20--50 L/min with or without supplementary oxygen and it has been reported to be an effective method to prevent post-extubation respiratory failure and reduce intubation failure rate in acute hypoxemic respiratory failure. Physiologically, HFNC oxygen therapy reduces functional dead space and decrease nasopharyngeal resistance and exerts a positive expiratory pressure effect and increase alveolar recruitment resulting in improving ventilation-perfusion mismatching[@B28]. It also contributes to humidify airway mucosa. In patients with stable hypercapnic COPD, the overall physiologic effects can lead to improve respiratory pattern (decreased respiration rate, increased tidal volume, increased airway pressure, decreased work of breathing, and improving hypercapnia, etc.) in a minor flow dependent pattern ([Figure 3](#F3){ref-type="fig"})[@B29][@B30].

Despite HFNC oxygen therapy showed beneficial effects in acute hypoxemic respiratory failure[@B31], the clinical significance of HFNC oxygen therapy in AECOPD has not been widely studied and the role of HFNC oxygen therapy in hypercapnic respiratory failure may be controversial. Recently, a small randomized controlled cross-over trial to evaluate the physiologic effects of titrated oxygen via HFNC compared with standard nasal prongs in Asian patients with AECOPD by measuring transcutaneous CO~2~ tension (PtCO~2~)[@B32]. The difference in PtCO~2~ adjusted for time zero was significantly lower after 30 minutes for HFNC compared with standard nasal prong (--1.4 mm Hg) (95% CI, --2.2 to --0.6, p=0.001) while there was no difference in SpO~2~ (p=0.96).

Conclusion
==========

As well as pharmacologic treatment, NIV is recommended as a beneficial strategy to reduce intubation risk in AECOPD with acute respiratory failure. Overcoming shortness of conventional NIV, some adjunctive modalities including NIV with helmet and helium-oxygen mixture have been tried. NIV with a helmet was noninferior to conventional facial mask in reducing intubation risk while avoiding commo complications of mask. Until now, NIV with helium-oxygen mixture didn\'t show any superiority compare to air-oxygen ventilation in terms of NIV failure rate and ICU mortality. HFNC oxygen therapy is another supportive strategy improving hypoxic respiratory failure and it also showed improvement in ventilatory variables and can be applicable in hypercapnic respiratory failure. As ECCO~2~R has been successfully applied in ARDS with protective hypercapnic ventilatory strategy, some reports showed effectiveness in reducing intubation in AECOPD with hypercapnic respiratory failure adjunctive with NIV. Currently, despite the shortness of evidence, efforts to improve efficacy of NIV will be continued and it may be expected to decrease the risk of intubation and invasive mechanical ventilation in AECOPD with acute respiratory failure.
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![Trends in initial ventilation. IMV: invasive mechanical ventilation; MV: mechanical ventilation; NIV: noninvasive ventilation. Adapted from Stefan et al. Chest 2015;147:959-68, with permission of Elsevier[@B14].](trd-81-99-g001){#F1}

![A patient with acute respiratory failure supported by noninvasive ventilation with a helmet (The patient provided written informed consent).](trd-81-99-g002){#F2}

![The effect of high-flow nasal cannula oxygen therapy on changes in mean airway pressure (A) and tidal volume (B) in patients with stable hypercapnic chronic obstructive pulmonary disease. nCPAP: nasal continuous positive airway pressure; nBiPAP: nasal bi-level positive airway pressure. Adapted from Braunlich et al. Int J Chron Obstruct Pulmon Dis 2016;11:1077-85, according to the Creative Commons license Dove Medical Press[@B30].](trd-81-99-g003){#F3}

###### Characteristics of ECMO and ECCO~2~R

![](trd-81-99-i001)

  Characteristic           ECMO                                                                                ECCO~2~R
  ------------------------ ----------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Circuit/bypass           Veno-venous bypass                                                                  Veno-venous bypass or arterio-venous bypass
  Blood drainage           From central vein (IJ, FV, SV)                                                      From central vein (IJ, FV, SV) or FA in AV configuration into central vein (IJ, FV, SV)
  Cannula dimension        16--31Fr                                                                            8--29Fr
  Cannula type             Two single cannulas or dual-lumen cannula                                           Two single cannulas or dual-lumen cannula
  Pump                     Centrifugal                                                                         Centrifugal or peristaltic
  EC blood flow            2.0--7.0 L/min                                                                      0.2--2.0 L/min
  CO~2~ clearance          100% VCO~2~, dependent mainly on sweep-gas flow dependent mainly on EC blood flow   10%--100% VCO~2~, dependent mainly on sweep-gas flow
  Oxygen deliver           Not significant                                                                     
  Anticoagulation target   ACT 1.5--2.0 times normal                                                           ACT 1.5 times normal
                           aPTT 1.2--1.8 times normal                                                          aPTT 1.5 times normal

ECMO: extracorporeal membrane oxygenation; ECCO~2~R: extracorporeal carbon dioxide removal; IJ: internal jugular vein; FV: femoral vein; SV: subclavian vein; VCO~2~: carbon dioxide production; EC: extracorporeal; ACT: activated clotting time; aPTT: activated partial thromboplastin time.
